33 related articles for article (PubMed ID: 38593345)
1. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
2. Substrate-selective positive allosteric modulation of PTPRD's phosphatase by flavonols.
Henderson IM; Marez C; Dokladny K; Smoake J; Martinez M; Johnson D; Uhl GR
Biochem Pharmacol; 2022 Aug; 202():115109. PubMed ID: 35636503
[TBL] [Abstract][Full Text] [Related]
3. Manipulating PTPRD function with ectodomain antibodies.
Qian Z; Song D; Ipsaro JJ; Bautista C; Joshua-Tor L; Yeh JT; Tonks NK
Genes Dev; 2023 Aug; 37(15-16):743-759. PubMed ID: 37669874
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.
Henderson IM; Zeng F; Bhuiyan NH; Luo D; Martinez M; Smoake J; Bi F; Perera C; Johnson D; Prisinzano TE; Wang W; Uhl GR
Biochem Pharmacol; 2022 Jan; 195():114868. PubMed ID: 34863978
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction.
Matsui Y; Imai A; Izumi H; Yasumura M; Makino T; Shimizu T; Sato M; Mori H; Yoshida T
FASEB J; 2024 Apr; 38(7):e23609. PubMed ID: 38593345
[TBL] [Abstract][Full Text] [Related]
7. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.
Uhl GR; Martinez MJ
Ann N Y Acad Sci; 2019 Sep; 1451(1):112-129. PubMed ID: 30648269
[TBL] [Abstract][Full Text] [Related]
8. [Morphology of basement membrane and associated matrix proteins in normal and pathological tissues].
Nerlich A
Veroff Pathol; 1995; 145():1-139. PubMed ID: 8638427
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase σ in proteoglycan-mediated neural regeneration regulation.
Chien PN; Ryu SE
Mol Neurobiol; 2013 Feb; 47(1):220-7. PubMed ID: 22956273
[TBL] [Abstract][Full Text] [Related]
11. Coreceptor functions of cell surface heparan sulfate proteoglycans.
Hayashida K; Aquino RS; Park PW
Am J Physiol Cell Physiol; 2022 May; 322(5):C896-C912. PubMed ID: 35319900
[TBL] [Abstract][Full Text] [Related]
12. Advancing therapeutics using antibody-induced dimerization of receptor tyrosine phosphatases.
Tremblay ML
Genes Dev; 2023 Aug; 37(15-16):678-680. PubMed ID: 37673461
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
